✦ LIBER ✦
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
✍ Scribed by Jeffrey J. Raizer; Sean Grimm; Marc C. Chamberlain; M. Kelly Nicholas; James P. Chandler; Kenji Muro; Steven Dubner; Alfred W. Rademaker; Jaclyn Renfrow; Markus Bredel
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 396 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.